Short Interest in Aptose Biosciences Inc. (NASDAQ:APTO) Rises By 1,012.9%

Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) saw a large increase in short interest in December. As of December 31st, there was short interest totalling 2,090,000 shares, an increase of 1,012.9% from the December 15th total of 187,800 shares. Based on an average daily trading volume, of 6,360,000 shares, the days-to-cover ratio is presently 0.3 days. Currently, 3.7% of the company’s stock are short sold.

Aptose Biosciences Stock Performance

NASDAQ APTO opened at $0.21 on Tuesday. The stock has a market capitalization of $12.73 million, a P/E ratio of -0.07 and a beta of 0.87. Aptose Biosciences has a 52 week low of $0.13 and a 52 week high of $2.42. The stock has a fifty day moving average of $0.25 and a 200-day moving average of $0.40.

Institutional Trading of Aptose Biosciences

A hedge fund recently raised its stake in Aptose Biosciences stock. Sigma Planning Corp grew its stake in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 71.3% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 401,750 shares of the biotechnology company’s stock after buying an additional 167,282 shares during the period. Sigma Planning Corp owned approximately 2.22% of Aptose Biosciences worth $165,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 26.62% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently issued reports on APTO shares. HC Wainwright reissued a “buy” rating and issued a $2.00 target price on shares of Aptose Biosciences in a research report on Friday. StockNews.com began coverage on shares of Aptose Biosciences in a report on Wednesday, January 8th. They issued a “hold” rating on the stock.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.